Skip to content

Advertisement

BMC Infectious Diseases

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

  • Evan B. Cunningham1Email authorView ORCID ID profile,
  • Behzad Hajarizadeh1,
  • Olav Dalgard2,
  • Janaki Amin1,
  • Margaret Hellard14,
  • Graham R Foster3,
  • Philip Bruggmann4,
  • Brian Conway5,
  • Markus Backmund6,
  • Geert Robaeys7, 8, 9,
  • Tracy Swan10,
  • Philippa S. Marks1,
  • Sophie Quiene1,
  • Tanya L Applegate1,
  • Martin Weltman11,
  • David Shaw12,
  • Adrian Dunlop13,
  • Julie Bruneau15,
  • Håvard Midgard2,
  • Stefan Bourgeois16,
  • Maria Christine Thurnheer17,
  • Gregory J Dore1,
  • Jason Grebely1 and
  • on behalf of the ACTIVATE Study Group
BMC Infectious DiseasesBMC series – open, inclusive and trusted201717:420

https://doi.org/10.1186/s12879-017-2517-3

Received: 11 January 2017

Accepted: 1 June 2017

Published: 13 June 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
11 Jan 2017 Submitted Original manuscript
26 Jan 2017 Reviewed Reviewer Report - Joop E Arends
3 Feb 2017 Reviewed Reviewer Report - Roberto Rossotti
4 Feb 2017 Reviewed Reviewer Report - Mario Masarone
7 Feb 2017 Reviewed Reviewer Report - Fabienne Marcellin
9 May 2017 Author responded Author comments - Evan Cunningham
Resubmission - Version 2
9 May 2017 Submitted Manuscript version 2
31 May 2017 Author responded Author comments - Evan Cunningham
Resubmission - Version 3
31 May 2017 Submitted Manuscript version 3
Publishing
1 Jun 2017 Editorially accepted
13 Jun 2017 Article published 10.1186/s12879-017-2517-3

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
The Kirby Institute, UNSW Sydney, Sydney, Australia
(2)
Akershus University Hospital, Oslo, Norway
(3)
The Liver Unit, Queen Mary University of London, London, UK
(4)
Arud Centres for Addiction Medicine, Zurich, Switzerland
(5)
Vancouver Infectious Diseases Center, Vancouver, Canada
(6)
Ludwig Maximilians-University Munich, Munich, Germany
(7)
Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, Belgium
(8)
Department of Hepatology, Leuven, Belgium
(9)
UHasselt, Hasselt, Belgium
(10)
Treatment Action Group, New York, USA
(11)
Nepean Hospital, Sydney, Australia
(12)
Royal Adelaide Hospital, Adelaide, Australia
(13)
School of Medicine and Public Health, University of Newcastle, Newcastle, Australia
(14)
Burnet Institute, Melbourne, Australia
(15)
Research Center, Centre Hospitalier de l’Universite de Montreal (CRCHUM), Quebec, Canada
(16)
Stuivenberg ZNA, Antwerp, Belgium
(17)
Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland

Advertisement